Exelixis Gets Breakthrough Tag for Cabozantinib for Thyroid Cancer

 Exelixis, Inc. (NASDAQ: EXEL) today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation to cabozantinib (CABOMETYX®) as a potential treatment for patients with differentiated thyroid cancer (DTC) that has progressed following prior therapy and who are radioactive iodine-refractory (if radioactive iodine is appropriate). The FDA’s Breakthrough Therapy Designation aims to expedite the development and review of drugs that are intended to treat serious or life-threatening diseases. To qualify for this designation, preliminary clinical evidence must indicate that the drug may demonstrate substantial improvement on at least one clinically significant endpoint over existing therapies.

https://www.biospace.com/article/releases/exelixis-announces-breakthrough-therapy-designation-granted-to-cabozantinib-for-the-treatment-of-patients-with-previously-treated-radioactive-iodine-refractory-differentiated-thyroid-cancer/